[HTML][HTML] 真实世界中表皮生长因子受体酪氨酸激酶抑制剂(吉非替尼或埃克替尼) 在非小细胞肺癌患者术后辅助治疗中的临床疗效分析
王化锋， 艾江山， 胡世宇 - Advances in Clinical Medicine, 2022 - hanspub.org
… first generation EGFR-TKIs (Gefitinib or Icotinib) as adjuvant … statistical difference in
patients receiving gefitinib or icotinib in … that gefitinib or icotinib be used as adjuvant therapy in …
patients receiving gefitinib or icotinib in … that gefitinib or icotinib be used as adjuvant therapy in …
ⅠB~ ⅢA 期非小细胞肺癌患者术后辅助靶向治疗研究进展
李若楠， 陈小科， 许元元， 谭强 - 上海交通大学学报(医学版), 2022 - xuebao.shsmu.edu.cn
… Among them, the first generation EGFR-TKIs are dominant in … , and icotinib has been approved
for postoperative adjuvant … Compared with the placebo, the third generation EGFR-TKIs …
for postoperative adjuvant … Compared with the placebo, the third generation EGFR-TKIs …
埃克替尼与吉非替尼治疗EGFR 突变型晚期肺腺癌的临床疗效比较
巫丽丽， 朱莹丽， 卓小露， 黄莉捺， 叶冬 - 中国癌症防治杂志, 2022 - zgazfz.com
… , differences of cellular immunity and humoral immunity indexes were compared between …
Results There was no significant difference between icotinib and gefitinib in terms of objective …
Results There was no significant difference between icotinib and gefitinib in terms of objective …